P-21 Activated Kinases in Liver Disorders.

Qiu, Xun; Xu, Hanzhi; Wang, Kai; Gao, Fengqiang; Xu, Xiao; He, Hong

Qiu, Xun; Xu, Hanzhi; Wang, Kai; Gao, Fengqiang; Xu, Xiao; He, Hong.

Afiliación

Qiu X; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Xu H; Zhejiang University School of Medicine, Hangzhou 310058, China.
Wang K; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Gao F; Zhejiang University School of Medicine, Hangzhou 310058, China.
Xu X; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
He H; Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China.

Cancers (Basel) ; 15(2)2023 Jan 16.

Article en En | MEDLINE | ID: mdl-36672500

Palabras clave

hepatic ischemia-reperfusion injury; hepatitis; liver cancer; liver fibrosis; p21 Activated Kinase; small molecular inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google